Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baratti, D.
Right arrow Articles by Santinami, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baratti, D.
Right arrow Articles by Santinami, M.
Related Collections
Right arrow Surgery
Annals of Surgical Oncology 10:291-296 (2003)
© 2003 Society of Surgical Oncology

ORIGINAL ARTICLES

Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution

D. Baratti, MD, A. Gronchi, MD, E. Pennacchioli, MD, L. Lozza, MD, M. Colecchia, MD, M. Fiore, MD and M. Santinami, MD

From the Departments of Surgery (DB, AG, EP, MF, MS), Radiation Oncology (LL), and Pathology (MC), National Cancer Institute of Milan, Italy.

Correspondence: Address correspondence and reprint requests to: Alessandro Gronchi, MD, Department of Surgery, National Cancer Institute of Milan, Via Venezian 1, 20133, Milano, Italy; Fax: 39-02-23902404; E-mail: alessandro.gronchi{at}istitutotumori.mi.it

Background: The natural history of chordoma is characterized by a high failure rate and a poor functional outcome. The purpose of this study was to review the long-term outcome of our institutional experience.

Methods: The clinical features, type of treatment, pathologic assessment, and follow-up of 56 consecutive patients with chordoma were reviewed.

Results: Fifty sacral and six mobile spine chordomas (median size, 13 cm; range, 2–30 cm) were treated at our center between January 1933 and December 2000. Twenty-eight patients affected by sacrococcygeal chordoma and operated on after 1977 form the basis of our study. Surgical margins were rated as wide in 11 cases, marginal in 13 cases, and intralesional in 4 cases. The median follow-up was 71 months (range, 15–200 months). Seventeen patients’ disease recurred. Ten patients died as a result of disease. Nine patients remained continuously free of disease. The estimated 5- and 10-year overall survival was, respectively, 87.8% and 48.9%; disease-free survival was 60.6% and 24.2%. Radiotherapy was considered for marginal and intralesional resections.

Conclusions: High sacral amputation can achieve a good rate of wide-margin resections for sacrococcygeal chordomas. Adjuvant radiotherapy may offset the negative effect in the prognosis of marginal resections.

Key Words: Chordoma • Sarcoma • Sacrococcygeal tumors • Prognosis • Surgery • Radiotherapy




This article has been cited by other articles:


Home page
 The OncologistHome page
R. Chugh, H. Tawbi, D. R. Lucas, J. S. Biermann, S. M. Schuetze, and L. H. Baker
Chordoma: The Nonsarcoma Primary Bone Tumor
Oncologist, November 1, 2007; 12(11): 1344 - 1350.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
Bluish Papule in a Middle-aged Man--Diagnosis
Arch Dermatol, December 1, 2005; 141(12): 1595 - 1600.
[Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
P. M. Weinberger, Z. Yu, D. Kowalski, J. Joe, P. Manger, A. Psyrri, and C. T. Sasaki
Differential Expression of Epidermal Growth Factor Receptor, c-Met, and HER2/neu in Chordoma Compared With 17 Other Malignancies
Arch Otolaryngol Head Neck Surg, August 1, 2005; 131(8): 707 - 711.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Society of Surgical Oncology.